Faculty of Health Sciences (ETDs)

Permanent URI for this communityhttps://hdl.handle.net/10539/37925

Browse

Filters

20232

Settings

Subject: search.filters.subject.Glucose control

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    HbA1c Control in Type 2 Diabetic Patients with Coronary Artery Disease
    (University of the Witwatersrand, Johannesburg, 2023-10) Mhlaba, Lona; Tsabedze, Nqoba; Mpanya, Dineo
    Background: Type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD) have an increased risk of recurrent cardiovascular events. These patients require optimal glucose control to prevent the progression of atherosclerotic cardiovascular disease (ASCVD). Current guideline recommendations target an HbA1c ≤7% to mitigate this risk. This study evaluated the level of HbA1c control in T2DM patients with CAD. Methods: This retrospective study assessed consecutive patients who presented with CAD to the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) between April 2017 and December 2019. The study included T2DM patients on anti-diabetic medication with angiographically confirmed CAD. HbA1c control was assessed using the HbA1c level measured at the index presentation and during the most recent follow-up visit. Results: The study population comprised 262 T2DM patients with a mean age was 61.3 ±10.4 years. Among the T2DM patients, 188 (71.8%) were males. At index presentation, 110 (42.1%) T2DM patients presented with ST-segment elevation myocardial infarction, 69 (26.4%) had non-ST-segment elevation myocardial infarction, 43 (16.5%) had unstable angina, and 39 (14.9%) had stable angina. The baseline median systolic blood pressure was higher in patients with an HbA1c ≤7% [136 mmHg (Interquartile range (IQR): 117-151) vs 124 mmHg (IQR: 112-142), p= 0.0121], compared to those with an HbA1c level above 7%. Furthermore, T2DM with an HbA1c ≤7% also had a higher median diastolic blood pressure [85 mmHg (IQR: 75.5-97) vs 78 mmHg (IQR: 71-88), p=0.0205]. After a median follow-up of 16.5 months (IQR: 7-29), 28.7% of the study participants had an HbA1c ≤7%. On multivariable regression analysis, patients with ST-segment depression on the resting electrocardiogram and index presentation had optimal glycaemic control (Odds ratio: 0.27, CI: 0.12-0.59, p= 0.001). Conclusion: After a median follow-up duration of 16.5 months, only 28.7% of T2DM patients with CAD had optimal glycaemic control. This finding underscores the substantial unmet need for optimal diabetes control in this very high-risk group.
  • Thumbnail Image
    Item
    Determinants of sub-optimal glycaemic control among patients enrolled in a medicine dispensing programme in Kwazulu-Natal: A cohort study, 2018 – 2021
    (University of the Witwatersrand, Johannesburg, 2023) Johnston, Leigh Clare
    Background: In South Africa, type 2 diabetes mellitus (T2DM) is a growing public health problem, thus, by 2030, 50% of T2DM patients, receiving treatment, must achieve optimal glycaemic control (haemoglobin A1c (HbA1c) ≤7%). The CCMDD (Central Chronic Medicines Dispensing and Distribution) programme allows glycaemically-stable patients to collect their medication from community-based pick-up points. While the CCMDD is a large public health programme, there is a paucity in stakeholder’s knowledge of T2DM patients glycaemic control over time. We determined glycaemic control for CCMDD-enrolled T2DM patients in eThekwini, South Africa from 2018-2021, as well as the rate and predictors of becoming sub-optimally controlled. Methods: We performed a cohort study, linking HbA1c data from the National Health Laboratory Service to CCMDD-enrolled patients in eThekwini, South Africa from 2018–2021. We included patients optimally controlled at their baseline HbA1c, and having ≥1 repeat test available. We used Kaplan Meier analysis to assess survival rates and Cox regression to determine associations between time to sub-optimal control (HbA1c > 7%) and several factors. Adjusted hazard ratios (aHR), 95% confidence interval (95% CI), and p-values are reported. Results: Of 41145 T2DM patients enrolled in the CCMDD, 7960 (19%) had an available HbA1c result over the study period. A quarter of patients (2147/7960; 27%) were optimally controlled at their baseline HbA1c. Of those controlled at baseline, 695 (32%) patients had a repeat test available, with 35% (242/695) changing their status to sub-optimal control. Patients prescribed dual-therapy had a higher risk of sub-optimal glycaemic control (aHR: 1.503; 95% CI: 1.16–1.95; p-value=0.002) compared to those on monotherapy. HbA1c testing frequency per national guidelines (aHR: 0.46; 95% CI: 0.24–0.91; p-value=0.024) was associated with a lower hazard of sub-optimal glycaemic control. Conclusions: HbA1c monitoring, in line with testing frequency guidelines, is needed to flag sub- optimally controlled patients who become ineligible for CCMDD enrolment. Patients receiving dual-therapy may require special consideration. Addressing these shortfalls can assist planning and implementation to achieve 2030 targets.